Published in J Med Genet on October 01, 1979
Hereditary angioedema and thyroid autoimmunity. J Clin Pathol (1987) 0.89
Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. J Exp Med (1974) 3.38
Genetic polymorphism of the third component of human complement (C'3). J Clin Invest (1968) 3.10
Linkage of HL-A and GBG. Vox Sang (1974) 2.23
Genetic polymorphism of C4 in man and localisation of a structural C4 locus to the HLA gene complex of chromosome 6. Nature (1976) 1.82
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
C3 polymorphism: genetic linkage relations. Clin Genet (1974) 1.00
Genetic independence between the HL--A system and deficits in the first and sixth components of complement. Tissue Antigens (1976) 0.98
Hereditary angioneurotic edema (HANE): Lack of close linkage between HLA haplotypes and C1 esterase inhibitor deficiency. Tissue Antigens (1977) 0.91
HLA types in two families with hereditary angioneurotic edema. Clin Immunol Immunopathol (1977) 0.91
Lack of linkage between gene(s) controlling the synthesis of the seventh component of complement and the HLA region on chromosome No. 6 in man. Hum Genet (1976) 0.91
Nonlinkage between C6 and chromosome 6 markers. Hum Genet (1977) 0.90
Linkage studies with C6. J Immunogenet (1977) 0.90
Genetic loci of components of the classical and alternate pathway of complement activation: a new dimension of the immunogenetic linkage group (HLA) on chromosome 6 in man. Hum Genet (1976) 0.89
Lack of linkage between hereditary angioedema and the A and B loci of the HLA system. Vox Sang (1978) 0.80
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
The nodD gene of Rhizobium leguminosarum is autoregulatory and in the presence of plant exudate induces the nodA,B,C genes. EMBO J (1985) 4.39
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
Cloning of the symbiotic region of Rhizobium leguminosarum: the nodulation genes are between the nitrogenase genes and a nifA-like gene. EMBO J (1983) 4.28
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison. Br Med J (1968) 3.89
Identification of the rhizobium strains in pea root nodules using genetic markers. J Gen Microbiol (1975) 3.78
DNA sequence of the Rhizobium leguminosarum nodulation genes nodAB and C required for root hair curling. Nucleic Acids Res (1984) 3.56
The Rhizobium leguminosarum nodulation gene nodF encodes a polypeptide similar to acyl-carrier protein and is regulated by nodD plus a factor in pea root exudate. EMBO J (1986) 3.55
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Further studies on the genetics of placental alkaline phosphatase. Ann Hum Genet (1967) 3.49
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Data on the incidence, segregation and linkage relations of the adenylate kinase (AK) polymorphism. Ann Hum Genet (1968) 2.91
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
Demonstration of a sex difference in recombination fraction in the loose linkage, Rh and PGM. Ann Hum Genet (1972) 2.56
Molecular characterization and regulation of the rhizosphere-expressed genes rhiABCR that can influence nodulation by Rhizobium leguminosarum biovar viciae. J Bacteriol (1992) 2.55
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Pericentric inversions of human chromosomes 9 and 10. Am J Hum Genet (1974) 2.40
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
The Rhizobium nodulation gene nodO encodes a Ca2(+)-binding protein that is exported without N-terminal cleavage and is homologous to haemolysin and related proteins. EMBO J (1990) 2.15
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Immunoglobulin heavy chain genes in humans are located on chromosome. Ann Hum Genet (1981) 1.85
The incidence of rare alleles determining electrophoretic variants: data on 43 enzyme loci in man. Ann Hum Genet (1974) 1.85
Genetics of the alkaline phosphatase polymorphism of the human placenta. Nature (1965) 1.83
Segregation of genetic markers in families with chromosome polymorphisms and structural rearrangements involving chromosome 1. Ann Hum Genet (1974) 1.81
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Evidence that DNA involved in the expression of nodulation (nod) genes in Rhizobium binds to the product of the regulatory gene nodD. Nucleic Acids Res (1987) 1.75
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet (1994) 1.62
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Structural relationship and complement fixing activity of sheep and other ruminant immunoglobulin G subclasses. Nature (1969) 1.57
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
One hundred requests for predictive testing for Huntington's disease. Clin Genet (1992) 1.52
A familial pericentric inversion of chromosome 22 with a recombinant subject illustrating a 'pure' partial monosomy syndrome. J Med Genet (1985) 1.51
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
Nodulation of legumes by Rhizobium: the recognized root? Cell (1986) 1.48
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
Association between digital ischaemia and malignant disease. Br Med J (1967) 1.46
Influence of diet on the "intestinal" component of serum alkaline phosphatase in people of different ABO blood groups and secretor status. Nature (1966) 1.44
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42
Analysis of pss genes of Rhizobium leguminosarum required for exopolysaccharide synthesis and nodulation of peas: their primary structure and their interaction with psi and other nodulation genes. Mol Gen Genet (1988) 1.41
Genetic epidemiology of Down's syndrome in Shetland. Hum Genet (1991) 1.41
Congenital asymmetry. J Med Genet (1966) 1.40
Studies on the terminal stages of complement lysis. Immunology (1973) 1.40
Evidence for linkage between the transferrin locus (Tf) and the serum cholinesterase locus (E1) in man. Ann Hum Genet (1966) 1.40
Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Pericentric inversion of a group C autosome: a study of three families. Ann Hum Genet (1968) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
Guidelines for human linkage maps: an international system for human linkage maps (ISLM, 1990). Genomics (1991) 1.37
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Chromosome survey of total population of mentally subnormal in North-East of Scotland. J Med Genet (1976) 1.32
Training of medical geneticists. J Med Genet (1978) 1.32
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31